SCHEMBL20524149

SCHEMBL20524149

CCOC(=O)c1cc(CCOC(=O)N(C)c2ccc(Cl)c(Cl)c2)on1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 3/20 0.41
▸ ALDH1A1 P00352 5/20 0.40
▸ HPGD P15428 4/20 0.40
▸ NOTUM Q6P988 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ GPBAR1 Q8TDU6 1/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ ACR P10323 1/20 0.38
▸ TP53 P04637 2/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ MAPT P10636 3/20 0.37
▸ GABRA2 P47869 1/20 0.37
▸ GABRB2 P47870 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ HDAC4 P56524 1/20 0.37
▸ HDAC1 Q13547 1/20 0.37
▸ HDAC7 Q8WUI4 1/20 0.37
▸ HDAC11 Q96DB2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29629610 0.85 HDAC6 (0.58) HDAC6ALDH1A1HPGDHSD17B10TP53
SCHEMBL21938821 0.85 HDAC6 (0.58) HDAC6ALDH1A1HPGDHSD17B10TP53
SCHEMBL20524144 0.76 HDAC6 (0.69) HDAC6ALDH1A1HPGDNOTUMHSD17B10
SCHEMBL29629613 0.76 HDAC6 (0.69) HDAC6ALDH1A1HPGDNOTUMHSD17B10
SCHEMBL15932308 0.76 HDAC6 (0.62) HDAC6ALDH1A1HPGDNOTUMHSD17B10
SCHEMBL15931903 0.74 MAPT (0.48) HDAC6ALDH1A1NOTUML3MBTL1ACR
SCHEMBL20524161 0.72 KMT2A (0.47) HDAC6ALDH1A1HPGDNOTUMHSD17B10
SCHEMBL29629617 0.72 HDAC6 (0.71) HDAC6ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL20524156 0.72 HDAC6 (0.71) HDAC6ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL15931958 0.72 MAPT (0.53) HDAC6ALDH1A1NOTUML3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200115350-A1 Isoxazole Hydroxamic Acids As Histone Deacetylase 6 Inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION 2020-04-16 — — US claimed
EP-3600295-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS The George Washington University, A Congressionally Chartered Not-For-Profit Corporation (US) 2020-02-05 — — EP claimed
WO-2018183701-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY (US) 2018-10-04 — — WO claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 — — US disclosed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 — — US disclosed
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-10-17 — — US disclosed
US-12024493-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-07-02 — — US disclosed
US-12024493-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-07-02 — — US disclosed
US-12024493-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-07-02 — — US disclosed
US-11472780-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY (US) 2022-10-18 — — US disclosed
US-20220153709-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2022-05-19 — — US disclosed
US-20220153709-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2022-05-19 — — US disclosed
US-20200115350-A1 Isoxazole Hydroxamic Acids As Histone Deacetylase 6 Inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION 2020-04-16 — — US disclosed
US-20200115350-A1 Isoxazole Hydroxamic Acids As Histone Deacetylase 6 Inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION 2020-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS HDAC3, HDAC1, HDAC4 HDAC6 10/4885ALDH1A1 452/4885HPGD 1083/4885
US-20220153709-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS HDAC1, HDAC7, HDAC5 HDAC6 10/4885ALDH1A1 179/4885HPGD 161/4885
US-11472780-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors HDAC1, HDAC7, HDAC5 HDAC6 10/4885ALDH1A1 166/4885HPGD 129/4885
US-12024493-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors HDAC1, HDAC7, HDAC5 HDAC6 10/4885ALDH1A1 179/4885HPGD 161/4885
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS HDAC1, HDAC7, HDAC5 HDAC6 10/4885ALDH1A1 179/4885HPGD 161/4885
US-20200115350-A1 Isoxazole Hydroxamic Acids As Histone Deacetylase 6 Inhibitors HDAC1, HDAC7, HDAC5 HDAC6 10/4885ALDH1A1 166/4885HPGD 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback